Cliona M. Rooney

Adverse events following infusion of T cells for adoptive immunotherapy: a 10-year experience.

Generation of EBV-specific CD4+ cytotoxic T cells from virus naive individuals.

Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the prevention and treatment of EBV-associated post-transplant lymphomas.

Immunotherapy to reconstitute immunity to DNA viruses.

Diagnosis and treatment of posttransplantation lymphoproliferative disease after hematopoietic stem cell transplantation.

Epstein-Barr virus-specific human T lymphocytes expressing antitumor chimeric T-cell receptors: potential for improved immunotherapy.

Adapting a transforming growth factor beta-related tumor protection strategy to enhance antitumor immunity.

Immunotherapy for post-transplant lymphoproliferative disease.

Autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for the treatment of persistent active EBV infection.

Generating CTLs against the subdominant Epstein-Barr virus LMP1 antigen for the adoptive immunotherapy of EBV-associated malignancies.

Identification of HLA-DP3-restricted peptides from EBNA1 recognized by CD4(+) T cells.

New insights into EBV-associated post-transplant lymphoproliferative disease.

Immunotherapy for Epstein-Barr virus-associated cancers in children.

The dynamics of herpesvirus and polyomavirus reactivation and shedding in healthy adults: a 14-month longitudinal study.

Selective depletion of donor alloreactive T cells without loss of antiviral or antileukemic responses.

Identification of a naturally processed HLA-DR-restricted T-helper epitope in Epstein-Barr virus nuclear antigen type 1.

树突状细胞天生多克隆人类细胞毒 T 淋巴细胞行使用的过继免疫治疗的永生细胞株的大规模扩张。

Induction of antigen-specific regulatory T cells following overexpression of a Notch ligand by human B lymphocytes.

Fiber-modified adenoviruses generate subgroup cross-reactive, adenovirus-specific cytotoxic T lymphocytes for therapeutic applications.

Human telomerase reverse transcriptase-specific T-helper responses induced by promiscuous major histocompatibility complex class II-restricted epitopes.

Adoptive T-cell therapy for EBV-associated post-transplant lymphoproliferative disease.

Adoptive T-cell therapy for Epstein-Barr virus-positive Hodgkin's disease.

A strategy for treatment of Epstein-Barr virus-positive Hodgkin's disease by targeting interleukin 12 to the tumor environment using tumor antigen-specific T cells.

Prompt versus preemptive intervention for EBV lymphoproliferative disease.

Evidence for the presentation of major histocompatibility complex class I-restricted Epstein-Barr virus nuclear antigen 1 peptides to CD8+ T lymphocytes.

Adoptive immunotherapy for posttransplantation viral infections.

The generation and characterization of LMP2-specific CTLs for use as adoptive transfer from patients with relapsed EBV-positive Hodgkin disease.

Conserved CTL epitopes on the adenovirus hexon protein expand subgroup cross-reactive and subgroup-specific CD8+ T cells.

Treatment of Epstein-Barr virus lymphoproliferative disease after hematopoietic stem-cell transplantation with hydroxyurea and cytotoxic T-cell lymphocytes.

Cellular therapy of Epstein-Barr-virus-associated post-transplant lymphoproliferative disease.

A comparison of gene transfer and antigen-loaded dendritic cells for the generation of CD4+ and CD8+ cytomegalovirus-specific T cells in HLA-A2+ and HLA-A2- donors.

Treatment of nasopharyngeal carcinoma with Epstein-Barr virus--specific T lymphocytes.

Cytotoxic T lymphocyte therapy for Epstein-Barr virus+ Hodgkin's disease.

Adoptive immunotherapy for EBV-associated malignancies.

Adenovirus as an emerging pathogen in immunocompromised patients.

Post-transplant lymphoproliferative disorders.

Cellular immunity to Epstein-Barr virus in liver transplant recipients treated with rituximab for post-transplant lymphoproliferative disease.

Human cytotoxic T lymphocytes with reduced sensitivity to Fas-induced apoptosis.

An inducible caspase 9 safety switch for T-cell therapy.

HLA type-independent generation of antigen-specific T cells for adoptive immunotherapy.

A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells.

Quantitative EBV viral loads and immunosuppression alterations can decrease PTLD incidence in pediatric liver transplant recipients.

Characterization of latent membrane protein 2 specificity in CTL lines from patients with EBV-positive nasopharyngeal carcinoma and lymphoma.

Hitchhiker's guide to the T cell.

Target antigen expression on a professional antigen-presenting cell induces superior proliferative antitumor T-cell responses via chimeric T-cell receptors.

Adenoviral infections in hematopoietic stem cell transplantation.

Improving T cell therapy for cancer.

Administration of latent membrane protein 2-specific cytotoxic T lymphocytes to patients with relapsed Epstein-Barr virus-positive lymphoma.

Assessing the safety of cytotoxic T lymphocytes transduced with a dominant negative transforming growth factor-beta receptor.

In vivo expansion of LMP 1- and 2-specific T-cells in a patient who received donor-derived EBV-specific T-cells after allogeneic stem cell transplantation.

Adoptive immunotherapy for Hodgkin's lymphoma.

Use of cytokine polymorphisms and Epstein-Barr virus viral load to predict development of post-transplant lymphoproliferative disorder in paediatric liver transplant recipients.

Treatment of solid organ transplant recipients with autologous Epstein Barr virus-specific cytotoxic T lymphocytes (CTLs).

T lymphocytes redirected against the kappa light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells.

Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals.

Quantification of a low cellular immune response to aid in identification of pediatric liver transplant recipients at high-risk for EBV infection.

Improving T cell therapy for cancer.

Contact-activated monocytes: efficient antigen presenting cells for the stimulation of antigen-specific T cells.

Dendritic cell function after gene transfer with adenovirus-calcium phosphate co-precipitates.

Epstein Barr virus specific cytotoxic T lymphocytes expressing the anti-CD30zeta artificial chimeric T-cell receptor for immunotherapy of Hodgkin disease.

Regression of experimental medulloblastoma following transfer of HER2-specific T cells.

Autologous designer antigen-presenting cells by gene modification of T lymphocyte blasts with IL-7 and IL-12.

Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer.

What influence has B-cell depletion on viral infections?

Co-expression of cytokine and suicide genes to enhance the activity and safety of tumor-specific cytotoxic T lymphocytes.

Inducible caspase 9 suicide gene to improve the safety of allodepleted T cells after haploidentical stem cell transplantation.

Gene-engineered varicella-zoster virus reactive CD4+ cytotoxic T cells exert tumor-specific effector function.

Identification of hexon-specific CD4 and CD8 T-cell epitopes for vaccine and immunotherapy.

Using dendritic cell maturation and IL-12 producing capacity as markers of function: a cautionary tale.

An inducible caspase 9 safety switch can halt cell therapy-induced autoimmune disease.

Antitumor activity of EBV-specific T lymphocytes transduced with a dominant negative TGF-beta receptor.

Cytotoxic T lymphocytes directed to the preferentially expressed antigen of melanoma (PRAME) target chronic myeloid leukemia.

Exploiting cytokine secretion to rapidly produce multivirus-specific T cells for adoptive immunotherapy.

Enhancing the in vivo expansion of adoptively transferred EBV-specific CTL with lymphodepleting CD45 monoclonal antibodies in NPC patients.

Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma.

In vivo fluorescent optical imaging of cytotoxic T lymphocyte migration using IRDye800CW near-infrared dye.

Production Assistance for Cellular Therapies (PACT): four-year experience from the United States National Heart, Lung, and Blood Institute (NHLBI) contract research program in cell and tissue therapies.

Genetic manipulation of tumor-specific cytotoxic T lymphocytes to restore responsiveness to IL-7.

T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model.

Functionally active virus-specific T cells that target CMV, adenovirus, and EBV can be expanded from naive T-cell populations in cord blood and will target a range of viral epitopes.

Immunotherapy for osteosarcoma: genetic modification of T cells overcomes low levels of tumor antigen expression.

Genetic modification of T cells with IL-21 enhances antigen presentation and generation of central memory tumor-specific cytotoxic T-lymphocytes.

Nucleofection of DCs to generate Multivirus-specific T cells for prevention or treatment of viral infections in the immunocompromised host.

Cytotoxic T lymphocyte therapy with donor T cells prevents and treats adenovirus and Epstein-Barr virus infections after haploidentical and matched unrelated stem cell transplantation.

Genome-wide mapping of PiggyBac transposon integrations in primary human T cells.

Optimization of the PiggyBac transposon system for the sustained genetic modification of human T lymphocytes.

Generation of Epstein-Barr virus-specific cytotoxic T lymphocytes resistant to the immunosuppressive drug tacrolimus (FK506).

Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients.

Derivation of human T lymphocytes from cord blood and peripheral blood with antiviral and antileukemic specificity from a single culture as protection against infection and relapse after stem cell transplantation.

Challenges of T cell therapies for virus-associated diseases after hematopoietic stem cell transplantation.

Antigen-specific cytotoxic T lymphocytes can target chemoresistant side-population tumor cells in Hodgkin lymphoma.

Accelerated production of antigen-specific T cells for preclinical and clinical applications using gas-permeable rapid expansion cultureware (G-Rex).

Allogeneic virus-specific T cells with HLA alloreactivity do not produce GVHD in human subjects.

IRAK-M removal counteracts dendritic cell vaccine deficits in migration and longevity.

Enhanced tumor trafficking of GD2 chimeric antigen receptor T cells by expression of the chemokine receptor CCR2b.

T cells expressing constitutively active Akt resist multiple tumor-associated inhibitory mechanisms.

Immunotherapeutic options for Epstein-Barr virus-associated lymphoproliferative disease following transplantation.

Adoptive transfer of EBV-specific T cells results in sustained clinical responses in patients with locoregional nasopharyngeal carcinoma.

A Th1-inducing adenoviral vaccine for boosting adoptively transferred T cells.

Enhancement of dendritic cells as vaccines for cancer.

High-avidity cytotoxic T lymphocytes specific for a new PRAME-derived peptide can target leukemic and leukemic-precursor cells.

Good manufacturing practice-grade cytotoxic T lymphocytes specific for latent membrane proteins (LMP)-1 and LMP2 for patients with Epstein-Barr virus-associated lymphoma.

Ex vivo gene transfer for improved adoptive immunotherapy of cancer.

Characterization and treatment of chronic active Epstein-Barr virus disease: a 28-year experience in the United States.

Posttransplant lymphoproliferative disease following liver transplantation.

Thunder and lightning: immunotherapy and oncolytic viruses collide.

CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients.

PiggyBac-mediated cancer immunotherapy using EBV-specific cytotoxic T-cells expressing HER2-specific chimeric antigen receptor.

Combining mTor inhibitors with rapamycin-resistant T cells: a two-pronged approach to tumor elimination.

Improving T-cell therapy for relapsed EBV-negative Hodgkin lymphoma by targeting upregulated MAGE-A4.

Cytotoxic T lymphocytes simultaneously targeting multiple tumor-associated antigens to treat EBV negative lymphoma.

Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma.

Aggressive peripheral CD70-positive t-cell lymphoma associated with severe chronic active EBV infection.

Inducible apoptosis as a safety switch for adoptive cell therapy.

Adoptive transfer of virus-directed T cells: will this fly for flu?

Production of good manufacturing practice-grade cytotoxic T lymphocytes specific for Epstein-Barr virus, cytomegalovirus and adenovirus to prevent or treat viral infections post-allogeneic hematopoietic stem cell transplant.

Replication-competent retroviruses in gene-modified T cells used in clinical trials: is it time to revise the testing requirements?

Generation of Polyclonal CMV-specific T Cells for the Adoptive Immunotherapy of Glioblastoma.

Rapidly generated multivirus-specific cytotoxic T lymphocytes for the prophylaxis and treatment of viral infections.

T-cell therapy in the treatment of post-transplant lymphoproliferative disease.

Large-scale ex vivo expansion and characterization of natural killer cells for clinical applications.